Neuromuscular Electrical Stimulation (NMES) and Muscle Protein Accretion (ES-PRO)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01615276
First received: May 30, 2012
Last updated: May 30, 2013
Last verified: May 2013

May 30, 2012
May 30, 2013
October 2012
January 2013   (final data collection date for primary outcome measure)
Tracer enrichment in the muscle biopsy [ Time Frame: 4 hours after protein ingestion ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01615276 on ClinicalTrials.gov Archive Site
Fractional synthetic rate (FSR) [ Time Frame: 0-4 hours after protein ingestion ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Neuromuscular Electrical Stimulation (NMES) and Muscle Protein Accretion (ES-PRO)
The Effect of Neuromuscular Electrical Stimulation on Post-prandial Muscle Protein Accretion in Healthy Elderly Men

In the present study, the effect of a bolus of intrinsically labeled milk directly after one-legged NMES will be studied.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Sarcopenia
  • Device: Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)
    One our of one-legged neuromuscular electrical stimulation (NMES)
  • Device: No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES
    No neuromuscular electrical stimulation (NMES) will be applied in the control leg
  • Placebo Comparator: Protein ingestion
    Protein ingestion directly after the contralateral leg received NMES
    Intervention: Device: No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES
  • Experimental: Protein ingestion after NMES
    Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)
    Intervention: Device: Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male
  • Age 65 - 85 years
  • 18.5 < BMI < 30 kg∙m2

Exclusion Criteria:

  • Type II diabetes
  • All co morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthrosis, arthritis, spasticity/rigidity, all neurological disorders, paralysis, hip/knee surgery).
  • Use of anticoagulants, blood diseases, allergy for lidocaine
  • Use of NSAIDs and acetylsalicylic acid
  • Patients suffering from PKU (Phenylketonuria)
  • Presence of implantable cardioverter defibrillator and/or pacemaker
  • Performed regular resistance type exercise in the past 6 months
Male
65 Years to 85 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01615276
MEC 12-3-020
No
Maastricht University Medical Center
Maastricht University Medical Center
Not Provided
Principal Investigator: Luc JC van Loon, PhD Maastricht UMC
Maastricht University Medical Center
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP